10 Gram	FOB Price:USD 1.0000 -2.0000

Min.Order :10 Gram
Purity: 99%
Payment Terms : L/C,D/A,D/P,T/T,,MoneyGram,Other

Keywords

Entacapone Entacapone powder 130929-57-6

Quick Details

Appearance:white powder
Application:Medicine，Health Food，Agriculture，Cosmetic Industry
PackAge:25kg/drum
ProductionCapacity:100|Metric Ton|Month
Storage:room temp
Transportation:by Sea,by land, by air

Superiority:

We promise our customer following items:

1.Support product customization:

We can provide OEM&ODM , Because we have a professional design team

2.Reasonable price:
We provide high quality products with competitive price in china,

3.Low moq:
No worry about the low moq, our moq is 1 gram or lower.

3.Good and efficient service,Fast Delivery
Fast respond save client's time, we promise to reply inquiry in 24 hours including holidays and send quotation sheet and other documents in 48 hours.

4.Super-good quality
We have strict quality control system .Good reputation in Market , And have the Third party test report is available

Pls contact us

If you have any further questions or need a sample,Please do not hesitate to contact us.

Xi'an Julong Bio-Tech Co., Ltd.

Details:

High purity 130929-57-6 Entacapone CAS NO.130929-57-6

BASIC INFORMATION

entacapone basic information

anti-parkinson's disease drugs pharmacokinetics chemical property application production method

product name:	entacapone
synonyms:	entacapone;2-cyano-3-(5-dihydroxyamino-3,4-dioxo-1-cyclohexa-1,5-dienyl)-n,n-diethyl-prop-2-enamide;entacapone f·s;or-611;(2e)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethyl-2-propenamide;comtan;comtes;comtess
cas:	130929-57-6
mf:	c14h15n3o5
mw:	305.29
einecs:
product categories:	intermediates & fine chemicals;pharmaceuticals;histone methyltransf
mol file:	130929-57-6.mol

entacapone chemical properties

mp	162-1630c
storage temp.	-20°c freezer
cas database reference	130929-57-6(cas database reference)

entacapone usage and synthesis

anti-parkinson's disease drugs	entacapone is an anti-parkinson's disease drug which is successfully developed by orion pharma company in swedish. it is a highly selective potent catechol-o-methyltransferase (comt) inhibitor, rarely penetrating the blood - brain barrier, and primarily acting in the intestinal tract. it is dose-dependent to decrease levels of 3-omd in serum and the brain, increasing levodopa, dopamine and dopac levels in the brain and significantly reducing the dose which is required to increase dopamine concentration in striatal. levodopa and carbidopa combining with comti can significantly increase the bioavailability of levodopa (3-4 times). activity of comti in red blood cell is reversible. when in 800mg dose, the maximum inhibitory activity is up to 82%, so entacapone combines with levodopa and carbidopa, which can be used for adjuvant therapy of idiopathic parkinson's disease.
pharmacokinetics	this product is rapid oral absorption, the bioavailability is a dose-dependent with the range of 30% to 45%. in the range of 5 ~ 800 mg, pharmacokinetics of entacapone (abbreviation: ent) is linear, peak plasma concentration is related to auc and dose. food does not affect the absorption of this product, 98% ent combines with plasma albumin, rarely distributing in tissues. in patients with parkinson disease (abbreviated: pd), and is required to take levodopa / carbidopa, the peak concentration of ent arrives within 1 ~ 2h. the rate of ent through the blood-brain barrier is low, the plasma elimination half-life is 1.5 ~ 3.5h. after oral administration, ent (e- configuration) is metabolized to z- isomer in the blood and is present in plasma and red blood cells. z- isomer has little impact on the clinical efficacy. its drug - time curve is similar to ent. z-ent accounts for about 5% of the total auc. ent and z-ent are acidified by glucose in the liver. after metabolism of ent: 10% excreted in the urine, 90% of ent excreted in the feces, only 0.2% excreted in the urine in phony drugs. while taking levodopa in pd patients, and oral ent 200 mg after elimination half-life of about 1 h, the body has no savings. pharmacokinetic study shows that in healthy persons and patients with pd, ent can increase the bioavailability of levodopa. in the short-term pd patients taking ent, auc of levodopa increase 25%, while the long-term taking ent can increase 50%. auc of 3-omd relatively reduces 60%. in these studies, they found that plasma peak time of levodopa will be extended. single dose of entacapone (while not taking levodopa / carbidopa), in patients with liver disease, the patient's auc and cmax is 2 times of the patients with normal liver function. we should adjust the dosage of the patient. in patients with mild to moderate kidney disease, it is not necessary to adjust the dosage. kidney patients receiving dialysis can extend dosing interval. the above information is edited by the chemicalbook of liu yujie.
chemical property	crystals, melting point 162--163 ℃.
application	as comt inhibitors, it is used to treat parkinson's disease.
production method	1.83 g 3,4- dihydroxy-5-nitrobenzaldehyde and 1.5g n, n- diethyl-cyanoacetamide and a catalytic amount of piperidine acetate are dissolved in 40ml of dry ethanol , followed by stirring overnight , 2.23 g crude product is obtained, yield 73%, melting point 153 ~ 156 ℃. heated at 90 ℃, the 3.0 kg crude product is dissolved in 8.0kg acetic acid (or formic acid) containing 80 g hbr (or 40ghcl).it is slowly cooled to 20 ℃, and stirred at this temperature for 20h, then at 15 ℃ stirred for 6h. the precipitated crystals were collected by filtration, carefully washed with cool (4 ℃) 1l toluene - acetic acid (1: l v / v) mixed solution, and washed with 1l cold toluene. it is dried at 45 ℃under vacuum and 2.4kg crystalline pure entacapone is obtained, yield 80%, melting point 162-163 ℃.
chemical properties	yellow crystalline solid
usage	(e)-isomer of entacapone polymorphic form a. peripherally acting inhibitor of catechol-o-methyl transferase (comt), an enzyme involved in the metabolism of catecholamine neurotransmitters and related drugs. antiparkinsonian
usage	antiparkinsinian;catechol-o-methyl transferase inhibitor
usage	this compound belongs to the cinnamic acid amides. these are amides of cinnamic acids. used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic parkinson's disease who experience the signs and symptoms of end-of-

PACKING&SHIPPING

OUR FACTORY

OUR TEAM

FAQ

Q: What's your MOQ
A: For the high value product, our MOQ starts from 1g and generally starts from 10gs. For other low, price product, our MOQ starts from 100g and 1kg.

Q: Is there a discount
A: Yes, for larger quantity, we always support with better price.

Q: How to confirm the Product Quality before placing orders
A: You can get free samples for some products, you only need to pay the shipping cost or arrange a courier to us and take the samples. You can send us your product specifications and requests, we will manufacture the products according to your requests

Q: How to start orders or make payments
A: You can send our your Purchase order (if your company has), or just send a simple confirmation by email or by Trade Manager, and we will send you Proforma Invoice with our bank details for your confirmation, then you can make payment accordingly.

Q: How do you treat quality complaint
First of all, our quality control will reduce the quality problem to near zero. If there is a quality problem caused by us, we will send you free goods for replacement or refund your loss.